Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 7/20 | 0.65 |
| ▸ | PAK4 | O96013 | 5/20 | 0.65 |
| ▸ | AURKA | O14965 | 5/20 | 0.65 |
| ▸ | IGF1R | P08069 | 3/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208636 | 0.93 | PAK1 (0.75) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216496 | 0.86 | PAK1 (0.86) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216591 | 0.86 | PAK1 (0.57) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216573 | 0.84 | PAK1 (0.59) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216551 | 0.83 | PAK1 (0.54) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216549 | 0.83 | PAK1 (0.54) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15216607 | 0.81 | PKN1 (0.54) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15209131 | 0.79 | PAK1 (1.00) | PAK1PAK4AURKAIGF1RPKN1 | |
| SCHEMBL15208743 | 0.78 | AURKA (0.59) | PAK1PAK4AURKAIGF1RNTRK1 | |
| SCHEMBL15216600 | 0.77 | PAK1 (0.52) | PAK1PAK4AURKAIGF1RPKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PAK1 1/4885PAK4 22/4885AURKA 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.